



Eleven Biotherapeutics
Investor Relations Department
245 First Street, Suite 1800
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: EBIO

Last Trade:	1.60
Trade Time:	4:00 PM ET September 22, 2017
Change:	-0.02 (1.235%)
Day Range	1.55 - 1.73
52-Week Range	0.90 - 3.23
Volume	289,575

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Eleven Biotherapeutics, Inc. is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on our Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine targeting antibody fragments with cytotoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.

We have designed TPTs with the potential to offer:

- Multiple advantages in treating cancer over traditional antibody drug conjugates.
- Effective tumor targeting with cancer cell-killing... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

September 22, 2017

[Eleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer](#)

September 5, 2017

[Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference](#)

August 14, 2017

[Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results](#)

August 7, 2017

[Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017](#)

August 3, 2017

[Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

March 24, 2017

[Annual Report \(10-K\)](#)

April 7, 2017

[Proxy Statement \(DEF 14A\)](#)

August 14, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

November 14, 2016

[Quarterly Report \(10-Q\)](#)